Anteris Technologies Global Corp (AVR) Stock Analysis

Verdict: AVOID

Severe cash burn ($79.8M FCF/yr) against $12.6M cash creates imminent dilution risk, overriding early-stage TAVR technology potential.

Investment score: 20/100

Analysis as of

Is Anteris Technologies Global Corp stock worth reviewing? The TradeMates thesis

The model evaluates Anteris Technologies as a high-risk speculative asset due to severe cash runway exhaustion ($12.58M cash vs $79.76M annual burn) and negative total equity, despite clinical promise in its DurAVR heart valve.

7-factor investment score

Anteris Technologies Global Corp opportunities and risks

What speaks for AVR

What speaks against AVR

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
AVRn/a341.5xn/a37.0%-4619.7%-11.5%
IARTn/a0.6x11.3x53.7%-0.4%3.9%
PRCTn/a2.9xn/a63.7%-32.5%-12.9%
CBLLn/a8.8xn/a88.9%-64.7%-6.3%
SIBNn/a3.8xn/a79.5%-6.9%-0.5%
VREX35.2x0.9x12.1x34.3%2.6%-2.6%
Peer mediann/a2.9xn/a63.7%-6.9%-2.6%

Frequently asked questions about Anteris Technologies Global Corp (AVR)

Is AVR stock a good investment?

The TradeMates model rates Anteris Technologies Global Corp as AVOID with an investment score of 20/100. The model evaluates Anteris Technologies as a high-risk speculative asset due to severe cash runway exhaustion ($12.58M cash vs $79.76M annual burn) and negative total equity, despite clinical promise in its DurAVR heart valve. This is algorithmic model output, not personal investment advice.

Is AVR stock a buy?

The TradeMates model verdict for AVR is AVOID with an investment score of 20/100. Treat this as a model signal to review, not a personal buy recommendation.